# A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

> **NCT05157776** · PHASE3 · UNKNOWN · sponsor: **Tongji University** · enrollment: 72 (estimated)

## Conditions studied

- NSCLC, Stage IIIA
- EGF-R Negative Non-Small Cell Lung Cancer
- ALK Negative NSCLC

## Interventions

- **DRUG:** PD-1 and chemotherapy

## Key facts

- **NCT ID:** NCT05157776
- **Lead sponsor:** Tongji University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-28
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05157776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05157776, "A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05157776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*